Ivacaftor and Lumacaftor

Therapeutic indications

Ivacaftor and Lumacaftor is indicated for:

Cystic fibrosis in patients homozygous for the F508del mutation in the CFTR gene

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lumacaftor/ivacaftor combination is are indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ivacaftor and Lumacaftor is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: ORKAMBI Film-coated tablet
Summary of Product Characteristics (SPC) 2023: ORKAMBI Granules
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈